EDMONTON, Dec. two, 2019 (Canada NewsWire through COMTEX) —
TSX | NYSE: ACB
Aurora Cannabis Inc. (the “Company” or “Aurora”) (NYSE ? TSX: ACB), the Canadian firm defining the future of cannabis worldwide, these days announced that a single of the Company’s oil goods has now been authorized for use beneath Ireland’s new Healthcare Cannabis Access Programme (MCAP). Aurora’s Higher CBD Oil Drops received approval from the Irish authorities and have now been added to a regulatory schedule by the Irish Minister of Well being enabling importation, prescribing and provide beneath the scheme and is to date, a single of only two goods to obtain such authorization.
Dr Shane Morris, Chief Item Officer at Aurora mentioned, “Aurora is pleased to be in a position to help individuals who are looking for remedy with higher high quality EU-GMP (great manufacturing practice) certified pharmaceutical-grade health-related cannabis in Ireland. We are quite proud to be a single of the very first authorized suppliers of health-related cannabis beneath the MCAP. We want to acknowledge the efforts created by quite a few people today, specifically the individuals and physicians who have campaigned for access to these medicines. We appear forward to far more of Aurora’s higher-high quality medicines getting authorized, so that far more individuals can advantage from the MCAP in Ireland. We will continue to perform closely with all parties and state agencies to facilitate additional availability.”
Beneath the new programme, a consultant can prescribe health-related cannabis for individuals beneath their care who have any of the following health-related circumstances:
-- Spasticity related with numerous sclerosis -- Intractable nausea and vomiting related with chemotherapy -- Extreme, refractory (remedy-resistant) epilepsy
The Healthcare Cannabis Access Programme was signed into law in June 2019 by Ireland’s Minister for Well being, Simon Harris. The programme will facilitate access to cannabis-primarily based health-related goods in line with legislation and is scheduled to run for five years.
Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 25 nations across 5 continents, Aurora is a single of the world’s biggest and top cannabis businesses. Aurora is vertically integrated and horizontally diversified across just about every crucial segment of the worth chain, from facility engineering and design and style to cannabis breeding and genetics study, cannabis and hemp production, derivatives, higher worth-add solution improvement, house cultivation, wholesale and retail distribution.
Extremely differentiated from its peers, Aurora has established a uniquely sophisticated, constant and effective production technique, primarily based on objective-constructed facilities that integrate top-edge technologies across all processes, defined by in depth automation and customization, resulting in the enormous scale production of higher-high quality constant solution. Developed to be replicable and scalable globally, our production facilities are developed to make cannabis at substantial scale, with higher high quality, sector-top yields, and low-per gram production fees. Every of Aurora’s facilities is constructed to meet European Union Superior Manufacturing Practices (“EU GMP”) requirements. Certification has been granted to Aurora’s very first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European health-related cannabis distributor Aurora Deutschland. All Aurora facilities are developed and constructed to the EU GMP typical.
In addition to the Company’s speedy organic development and robust execution on strategic M&A, which to date contains 17 wholly owned subsidiary businesses – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, Whistler, Chemi Pharmaceutical, and Hempco – Aurora is distinguished by its reputation as a companion and employer of option in the worldwide cannabis sector, possessing invested in and established strategic partnerships with a variety of top innovators, which includes: Radient Technologies Inc. (TSXV: RTI), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), Higher Tide Inc. (CSE: HITI), EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty Group (private), and Wagner Dimas (private).
Aurora’s Prevalent Shares trade on the TSX and NYSE beneath the symbol “ACB”, and is a constituent of the S&P/TSX Composite Index.
For far more data about Aurora, please take a look at our investor web site, investor.auroramj.com
Terry Booth, CEO Aurora Cannabis Inc.
Forward seeking statements
This news release contains statements containing particular “forward-seeking information” inside the which means of applicable securities law (“forward-seeking statements”). Forward-seeking statements are regularly characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other related words, or statements that particular events or circumstances “may” or “will” take place. These forward-seeking statements are only predictions. Several assumptions had been employed in drawing the conclusions or generating the projections contained in the forward-seeking statements all through this news release. Forward-seeking statements are primarily based on the opinions, estimates and assumptions of management in light of management’s expertise and perception of historical trends, present circumstances and anticipated developments at the date the statements are created, such as present and future marketplace circumstances, the present and future regulatory atmosphere and future approvals and permits. Forward-seeking statements are topic to a wide variety of dangers, uncertainties and other components that management believes to be relevant and affordable in the situations could result in actual events, final results, level of activity, overall performance, prospects, possibilities or achievements to differ materially from these projected in the forward-seeking statements, which includes basic enterprise and financial circumstances, alterations in laws and regulations, solution demand, alterations in costs of needed commodities, competitors and other dangers, uncertainties and components set out beneath the heading “Risk Factors” in the Company’s annual data type dated September 10, 2019 (the “AIF”) and filed with Canadian securities regulators readily available on the Company’s issuer profile on SEDAR at www.sedar.com. The Business cautions that the list of dangers, uncertainties and other components described in the AIF is not exhaustive and other components could also adversely impact its final results. Readers are urged to look at the dangers, uncertainties and assumptions meticulously in evaluating the forward-seeking statements and are cautioned not to location undue reliance on such data. The Business is beneath no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-seeking statements, no matter whether as a outcome of new data, future events or otherwise, except as expressly needed by applicable securities laws.
View original content material to download multimedia:http://www.prnewswire.com/news-releases/aurora-receives-very first-approval-for-medicinal-cannabis-solution-in-ireland-300967234.html
Supply Aurora Cannabis Inc.
View original content material to download multimedia: http://www.newswire.ca/en/releases/archive/December2019/02/c0346.html
Supply: Aurora Cannabis Inc.
For Media: Laura Gallant, +1.437.992.8429, [email protected] For Investors: Rob Kelly, +1.647.331.7228, [email protected]
Copyright (C) 2019 CNW Group. All rights reserved.